Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShire Regulatory News (SHP)

  • There is currently no data for SHP

Form 8.5 (EPT/RI) - Amendment

2 Jan 2019 11:12

RNS Number : 9501L
Citigroup Global Markets Limited
02 January 2019
Β 

Β 

Β 

Β 

Amendment - Section 2(a) & (b)

FORM 8.5 (EPT/RI)

Β 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH

RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Name of exempt principal trader:

Citigroup Global Markets Limited

(b) Name of offeror/offeree in relation to whoserelevant securities this form relates:Use a separate form for each offeror/offeree

Shire plc

(c) Name of the party to the offer with which exemptprincipal trader is connected:

Shire plc

(d) Date dealing undertaken:

28 December 2018

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?If it is a cash offer or possible cash offer, state "N/A"

YESTakeda Pharmaceutical Company Limited

Β 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Β 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

Β 

The currency of all prices and other monetary amounts should be stated.

Β 

(a) Purchases and sales

Β 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

ADR

Purchase

100

USDΒ 173.9400

USDΒ 173.9400

ADR

Sale

100

USDΒ 173.9400

USDΒ 173.9400

5p ordinary

Purchase

53,045

GBPΒ 45.6000

GBPΒ 45.3600

5p ordinary

Sale

53,045

GBPΒ 45.6000

GBPΒ 45.3600

5p ordinary

Purchase

199,246

USD 57.7489

USD 57.7489

Β 

(b) Cash-settled derivative transactions

Β 

Β 

Class of relevant security

Product description e.g. CFD

Nature of dealinge.g. opening/closing along/short position,increasing/reducing along/short position

Number of reference securities

Price per unit

5p ordinary

TRS

Increasing Short Position

90,000

USD 57.7489

5p ordinary

TRS

Increasing Short Position

109,246

USD 57.7489

Β 

(c) Stock-settled derivative transactions (including options)

Β 

(i) Writing, selling, purchasing or varying

Β 

Class of relevant security

Product description e.g. call option

Writing, purchasing,selling,varying etc.

Number of securities towhich option relates

Exercise price per unit

Typee.g. American,European etc.

Expiry date

Option money paid/ received per unit

Β 

Β 

(ii) Exercise

Β 

Β 

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number ofsecurities

Exercise price per unit

Β 

(d) Other dealings (including subscribing for new securities)

Β 

Β 

Class of relevant security

Nature of dealinge.g. subscription, conversion

Details

Price per unit(if applicable)

Β 

3. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding,formal or informal, relating to relevant securities which may be an inducement to dealor refrain from dealing entered into by the exempt principal trader making thedisclosure and any party to the offer or any person acting in concert witha party to the offer:

Β 

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

None

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, betweenthe exempt principal trader making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

Β 

If there are no such agreements, arrangements or understandings, state "none"

None

Β 

Date of disclosure:

2 January 2019

Contact name:

Connor McLaughlin

Telephone number:

02895 955 328

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory InformationService and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
FERBTMBTMBMMBPL
Date   Source Headline
10th Dec 20183:30 pmRNSForm 8.3 - Shire PLC
10th Dec 20183:29 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
10th Dec 20183:27 pmRNSForm 8.3 - Shire plc
10th Dec 20183:25 pmGNWElliott Capital Advisors, L.P: Form 8.3 - Takeda Pharmaceutical Company Limited
10th Dec 20183:20 pmRNSForm 8.3 - Shire plc
10th Dec 20183:16 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
10th Dec 20183:13 pmRNSForm 8.5 (EPT/NON-RI)
10th Dec 20183:07 pmRNSForm 8.5 (EPT/RI) - Replacement of SHIRE
10th Dec 20183:06 pmRNSForm 8.5 (EPT/RI) - Replacement of SHIRE
10th Dec 20183:03 pmRNSForm 8.5 (EPT/RI) - Replacement of SHIRE
10th Dec 20182:44 pmRNSForm 8.3 - Shire plc
10th Dec 20182:42 pmPRNForm 8.3 - Shire Plc
10th Dec 20182:41 pmRNSForm 8.3 - [Shire Plc]
10th Dec 20182:38 pmEQSForm 8.3 - The Vanguard Group, Inc.: Shire plc
10th Dec 20182:22 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
10th Dec 20182:21 pmRNSForm 8.3 - Shire plc
10th Dec 20182:13 pmRNSForm 8.3 - Shire plc
10th Dec 20181:18 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
10th Dec 20181:12 pmRNSForm 8.3 - Shire plc
10th Dec 201812:02 pmBUSForm 8.3 - SHIRE PLC
10th Dec 201811:45 amRNSForm 8.5 (EPT/RI)
10th Dec 201811:25 amRNSForm 8.5 (EPT/NON-RI)- Shire Plc
10th Dec 201810:56 amRNSForm 8.5 - Shire Plc
10th Dec 201810:50 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
10th Dec 201810:49 amRNSForm 8.3 - Shire PLC
10th Dec 201810:48 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
10th Dec 201810:47 amRNSForm 8.5 (EPT/RI) - SHIRE PLC
10th Dec 201810:47 amRNSForm 8.5 (EPT/RI)
10th Dec 201810:44 amRNSForm 8.5 (EPT/NON-RI)
10th Dec 201810:41 amRNSForm 8.5 (EPT/NON-RI) - SHIRE PLC
10th Dec 201810:28 amRNSForm 8.5 (EPT/RI)- Shire plc
10th Dec 20188:11 amBUSForm 8.3 - SHIRE PLC - Amendment
10th Dec 20187:15 amRNSForm 8.3 - Shire plc
10th Dec 20187:13 amRNSForm 8.3 - Takeda Pharmaceutical Company Limited
10th Dec 20187:07 amRNSForm 8.3 - Shire Plc
7th Dec 20183:58 pmRNSForm 8.5 (EPT/NON-RI)
7th Dec 20183:56 pmRNSForm 8.5 (EPT/NON-RI)
7th Dec 20183:25 pmGNWElliott Capital Advisors, L.P: Form 8.3 - Takeda Pharmaceutical Co.Ltd
7th Dec 20183:25 pmGNWElliott Capital Advisors, L.P: Form 8.3 - Shire PLC
7th Dec 20183:21 pmRNSForm 8.3 - Takeda Pharmaceutical
7th Dec 20183:20 pmRNSForm 8.3 - Shire plc
7th Dec 20183:20 pmRNSForm 8.3 - Shire plc
7th Dec 20183:00 pmBUSForm 8.3 - Shire PLC
7th Dec 20182:58 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Dec 20182:47 pmRNSForm 8.5 (EPT/RI) - Amendment
7th Dec 20182:47 pmRNSForm 8.3 - Takeda Pharmaceutical Company Limited
7th Dec 20182:46 pmRNSForm 8.5 (EPT/RI) - Amendment
7th Dec 20182:46 pmRNSForm 8.3 - Shire plc
7th Dec 20182:45 pmRNSForm 8.5 (EPT/RI) - Amendment
7th Dec 20182:43 pmRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.